유도만능줄기세포 시장 규모, 점유율, 동향 분석 보고서 : 유래 세포 유형별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Induced Pluripotent Stem Cells Market Summary

The global induced pluripotent stem cells market size was valued at USD 2.0 billion in 2025 and is projected to grow from USD 2.2 billion in 2026 to USD 4.8 billion by 2033, at a CAGR of 11.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 35.8% in 2025. The rising prevalence of chronic diseases, increasing research and development activities in stem cell therapies, and growing focus on personalized medicine drive the iPSC market growth.

Global Induced Pluripotent Stem Cells Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global induced pluripotent stem cells market on the basis of derived cell type, application, end use, and region:

• Derived Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
• Hepatocytes
• Fibroblasts
• Keratinocytes
• Amniotic Cells
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Development
• Tissue Engineering & Regenerative Medicine
  • Neurology
  • Orthopedics
  • Oncology
  • Cardiovascular and Myocardial Infraction
  • Diabetes
  • Others
• Toxicology Research
• Disease Modeling
• End use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Derived Cell Type Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End-use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Application of Regenerative Medicine
    • 3.2.1.2. Technology Advancement in iPSC Production
    • 3.2.1.3. Growing Prevalence of Chronic and Degenerative Diseases
    • 3.2.1.4. Expanding Applications in Disease Modeling and Drug Discovery
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent Process Control and Regulatory Challenges
    • 3.2.2.2. Challenges in Large-Scale Commercialization and Reproducibility
    • 3.2.2.3. High Cost of Production
  • 3.2.3. Market Opportunities Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Derived Cell Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Induced Pluripotent Stem Cells Market: Derived Cell Type Movement Analysis
• 4.3. Hepatocytes
  • 4.3.1. Hepatocytes Market, 2021 - 2033 (USD Million)
• 4.4. Fibroblasts
  • 4.4.1. Fibroblasts Market, 2021 - 2033 (USD Million)
• 4.5. Keratinocytes
  • 4.5.1. Keratinocytes Market, 2021 - 2033 (USD Million)
• 4.6. Amniotic Cells
  • 4.6.1. Amniotic Cells Market, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Segment Dashboard
• 5.2. Induced Pluripotent Stem Cells Market: Application Movement Analysis
• 5.3. Drug Development
  • 5.3.1. Drug Development Market, 2021 - 2033 (USD Million)
• 5.4. Tissue Engineering & Regenerative Medicine
  • 5.4.1. Tissue Engineering & Regenerative Medicine Market, 2021 - 2033 (USD Million)
  • 5.4.2. Neurology
    • 5.4.2.1. Neurology Market, 2021 - 2033 (USD Million)
  • 5.4.3. Orthopedics
    • 5.4.3.1. Orthopedics Market, 2021 - 2033 (USD Million)
  • 5.4.4. Oncology
    • 5.4.4.1. Oncology Market, 2021 - 2033 (USD Million)
  • 5.4.5. Cardiovascular and Myocardial Infarction
    • 5.4.5.1. Cardiovascular and Myocardial Infarction Market, 2021 - 2033 (USD Million)
  • 5.4.6. Diabetes
    • 5.4.6.1. Diabetes Market, 2021 - 2033 (USD Million)
  • 5.4.7. Others
    • 5.4.7.1. Others Market, 2021 - 2033 (USD Million)
• 5.5. Toxicology Research
  • 5.5.1. Toxicology Research Market, 2021 - 2033 (USD Million)
• 5.6. Disease Modeling
  • 5.6.1. Disease Modeling Market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. Segment Dashboard
• 6.2. Induced Pluripotent Stem Cells Market: End-use Movement Analysis
• 6.3. Academic & Research Institutes
  • 6.3.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Induced Pluripotent Stem Cells Market Share By Region, 2025 & 2033
• 7.2. North America
  • 7.2.1. North America Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. U.S. Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Canada Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Competitive Scenario
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Mexico Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. UK Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Germany Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. France Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Italy Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Spain Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Denmark Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Sweden Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Norway Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Japan Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. China Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. India Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Australia Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Thailand Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. South Korea Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Brazil Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Argentina Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. South Africa Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Saudi Arabia Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. UAE Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Kuwait Induced Pluripotent Stem Cells Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Share/ Position Analysis, 2025
• 8.3. Strategy Mapping
• 8.4. Company Profiles/Listing
  • 8.4.1. STEMCELL Technologies Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Cellular Engineering Technologies Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. REPROCELL Inc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Takara Bio, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Axol Bioscience Ltd.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Fate Therapeutics, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. FUJIFILM Cellular Dynamics, Inc.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Cynata Therapeutics Limited
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Evotec SE
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Astellas Pharma Inc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives